Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double Blind Randomized Study to Assess the Efficacy of BF2.649 Compared to Placebo in add-on to Sodium Oxybate in the Treatment of Narcoleptic Patients With Residual Excessive Daytime Sleepiness (EDS) During 8 Weeks

Next Previous
X
Search
Trial Profile

Double Blind Randomized Study to Assess the Efficacy of BF2.649 Compared to Placebo in add-on to Sodium Oxybate in the Treatment of Narcoleptic Patients With Residual Excessive Daytime Sleepiness (EDS) During 8 Weeks

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pitolisant (Primary) ; Sodium oxybate
  • Indications Narcolepsy
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONY-IV
  • Sponsors Bioprojet

    • Most Recent Events

    • 20 Jan 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 03 Sep 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 02 Mar 2013 Planned number of patients changed from 50 to 60 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top